Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Major Depressive Disorder
NCT05675800Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by Washington University School of Medicine. Planned start Jan 2024; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05675800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675800.